Skip to main content

Adstiladrin FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 21, 2022.

FDA Approved: Yes (First approved December 16, 2022)
Brand name: Adstiladrin
Generic name: nadofaragene firadenovec-vncg
Dosage form: Suspension for Intravesical Use
Company: Ferring Pharmaceuticals Inc.
Treatment for: Bladder Cancer

Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Development timeline for Adstiladrin

Dec 16, 2022Approval FDA Approves Adstiladrin (nadofaragene firadenovec-vncg) for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.